ImmuPharma PLC

NEW
CHIX:IMMl (UK)  
£ 0.037 (0%) Jul 10
At Loss
P/B:
40.45
Market Cap:
£ 25.24M ($ 33.76M)
Enterprise V:
£ 23.89M ($ 31.95M)
Volume:
0
Avg Vol (2M):
1.14K
Trade In:
Volume:
0
At Loss
Avg Vol (2M):
1.14K

Business Description

Description
ImmuPharma PLC focuses on the research, development, and commercialisation of pioneering and novel drugs in specialist therapeutic areas within the pharmaceutical industry. The company's pipeline products are P140, CDx, Kapiglucagon, BioAMB, and BioCIN.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
No Debt
Equity-to-Asset
0.37
Piotroski F-Score
2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
9-Day RSI
0.07
14-Day RSI
1.08
3-1 Month Momentum %
-14.23
6-1 Month Momentum %
-39.73

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
1.52
Quick Ratio
1.52
Cash Ratio
1.13

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-14.7
Shareholder Yield %
-5.02

Profitability Rank

Name Current Vs Industry Vs History
ROE %
-1127.65
ROA %
-122.24
ROIC %
-315.14
3-Year ROIIC %
-43.05
ROC (Joel Greenblatt) %
-2937.56
ROCE %
-1349.69

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio
40.45
EV-to-EBIT
-11.04
EV-to-EBITDA
-11.22
EV-to-FCF
-10.07
Earnings Yield (Greenblatt) %
-9.06
FCF Yield %
-9.4

Financials (Next Earnings Date:2026-08-06 Est.)

CHIX:IMMl's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

ImmuPharma PLC Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil £)
EPS (TTM) (£) -0.004
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % -
14-Day RSI 1.08
14-Day ATR (£) 0.000246
20-Day SMA (£) 0.04026
12-1 Month Momentum % -
52-Week Range (£) 0.0372 - 0.149
Shares Outstanding (Mil) 623.91

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

ImmuPharma PLC Filings

Filing Date Document Date Form
No Filing Data

ImmuPharma PLC Stock Events

Financials Calendars
Event Date Price (£)
Second quarter earnings results for 2026 2026-08-06 In 24 days
General meeting for 2025 2026-06-25 10:00 0.04 (+0.00%)
Annual report for 2025 2026-06-02 0.04 (+0.00%)
Fourth quarter earnings results for 2025 2026-05-27 0.04 (+0.00%)
Second quarter earnings results for 2025 2025-08-06 --
General meeting for 2024 2025-06-12 11:00 --
Annual report for 2024 2025-05-19 --
Fourth quarter earnings results for 2024 2025-05-19 --
Second quarter earnings results for 2024 2024-09-09 --
Show
Entries

ImmuPharma PLC Frequently Asked Questions

What is ImmuPharma PLC(CHIX:IMMl)'s stock price today?
The current price of CHIX:IMMl is £0.04. The 52 week high of CHIX:IMMl is £0.15 and 52 week low is £0.04.
When is next earnings date of ImmuPharma PLC(CHIX:IMMl)?
The next earnings date of ImmuPharma PLC(CHIX:IMMl) is 2026-08-06 Est..
Does ImmuPharma PLC(CHIX:IMMl) pay dividends? If so, how much?
ImmuPharma PLC(CHIX:IMMl) does not pay dividend.

Press Release

Subject Date
No Press Release

Articles on ImmuPharma PLC

No articles.